To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.~The Phase 1a part of the study is a dose-escalation and dose-optimization phase investigating NG-641 administration by intravenous (IV) infusion in a range of tumour types.~The Phase 1b part of the study will investigate the selected optimized multicycle dosing regimen as a monotherapy in up to three cohorts of patients with specific tumour types (Dose Expansion Cohorts A, B and C).
To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.